It is nowadays fashionable to question everyone in authority, and there is no shortage of self-appointed watchdogs who aim to make sure that things that happen are happening as they should.
It is nowadays fashionable to question everyone in authority, and there is no shortage of self-appointed watchdogs who aim to make sure that things that happen are happening as they should. The drug industry and drug regulatory authorities have been among the most conspicuous targets of this intense monitoring, on everything from questionable payments to promote drug sales to suspicions of bending too easily to the whims of manufacturers.
Many of these challenges have come from organizations which already have with a perceptible and even an avowed agenda: politicians, health activists, consumer and patient organisations, the liberal media… A surprising recruit to the ranks of ipsos custodies was that bastion of the Establishment, the UK Daily Mail (whose more typical territory is represented by one of its headlines today: “Feeling Sad? Then Hit the Shops… it Really Works!). A recent front-page lead story in the Mail leveled accusations of massive abuse of public funds at the British National Institute for Health and CareExcellence, the body that decides on which drugs may be prescribed under the national health service.
NICE had, said the Mail, “racked up $190,000 on taxpayer-funded credit cards in the past two and a half years, including over $8,000 on luxury hotels”. In a frenzy of righteous indignation, the story went on to list alleged excesses as far afield as Japan and Santa Monica, claiming “officials rule out use of life-saving drugs due to cost but spend thousands on five-star hotels and shopping sprees.” The story was immediately contested by NICE, and days later, the Mail published (on page 2) a correction. “An article about spending by officials of NICE, the NHS drugs’ watchdog on January 11 said that $5,500 was spent at a chain of champagne bars. We have been asked to make clear that this sum was for room hire and catering for committee meetings on two occasions at the Royal College of General Practitioners and at the Commonwealth Club.”
NICE has presented a detailed breakdown of the alleged spending sprees. The $865.30 identified by the Mail spent at the five star Ritz Carlton in Osaka, Japan was for accommodation during a government-led delegation to Japan. The $2287.21 at the Hotel Melia in Berlin was for accommodation for staff at a conference on clinical guidelines in Berlin, and the $1,308 at the Miramar luxury hotel and spa in Santa Monica, California was similarly for accommodation during an official visit to US-based life sciences companies. A bill of $1,034 “in a store specializing in bar equipment and bottle openers” was for jugs, glasses and coffee flasks for meetings and events, and $1,034 “on a website for home and garden equipment” was for office storage cupboards. The urbane response from NICE stops short of pointing out the obvious – that $190,000 in such expenses over two years for a body responsible for overseeing a multi-billion healthcare budget is in any case peanuts. But it does pointedly observe in a letter to the paper’s editor: “You have a right, you might say a duty, to examine how public bodies spend their money. But if you’re going to do it, you should do so with due care and attention. You haven’t done so in this case and as a consequence you’ve both misled the public and damaged our reputation.”
Given the high profile of everything related to medicines, to healthcare, and to regulatory decision-making, it is no surprise-and no bad thing-that there is plenty of attention to propriety. The Mail episode is yet another lamentable example of a failure by custodians of virtue to meet the same high standards of accuracy and fidelity that they claim to require of those under scrutiny.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.